BioCryst (BCRX) Stock Forecast & Price Target

Compare

2,281 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BCRX Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

BioCryst

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BCRX Stock 12 Month Forecast

Average Price Target

$16.92

▲(103.86% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for BioCryst in the last 3 months. The average price target is $16.92 with a high forecast of $30.00 and a low forecast of $8.50. The average price target represents a 103.86% change from the last price of $8.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","18":"$18","31":"$31","11.5":"$11.5","24.5":"$24.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,11.5,18,24.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.95,9.646153846153846,11.342307692307692,13.038461538461538,14.734615384615385,16.43076923076923,18.126923076923077,19.823076923076922,21.51923076923077,23.215384615384615,24.91153846153846,26.607692307692307,28.303846153846152,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.95,8.64,9.33,10.02,10.71,11.400000000000002,12.09,12.780000000000001,13.470000000000002,14.160000000000002,14.850000000000001,15.540000000000003,16.23,{"y":16.92,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.95,7.992307692307692,8.034615384615385,8.076923076923077,8.11923076923077,8.161538461538461,8.203846153846154,8.246153846153847,8.288461538461538,8.330769230769231,8.373076923076923,8.415384615384616,8.457692307692307,{"y":8.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.67,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.11,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$16.92

Lowest Price Target$8.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dex Genotek

TR | OpenAI - 4o

$8.5

Hold

2.41%

Upside

Reiterated

08/08/25

Andrew Fein

H.C. Wainwright

$30

Buy

261.45%

Upside

Reiterated

08/05/25

BioCryst's Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy RatingValuation and Risks. We reiterate our Buy rating and $30 price target. Our price target of $30 is based on the equally weighted average of: (a) $34.2/ share, as a 30x multiple of taxed and diluted FY35 GAAP EPS of $3.54 discounted back to and (b) an NPV of $25.97/share (discount rate 12%, growth rate 1%). Risks to our investment thesis and target price include: (1) failure of agents in clinical trials; (2) failure to secure further regulatory approval; and (3) a smaller than anticipated commercial opportunity, due to prophylaxis market size or degree of long-term expansion, competition, or pricing.

Laura Chico

Wedbush

$18

Buy

116.87%

Upside

Reiterated

08/05/25

Wedbush Sticks to Their Buy Rating for BioCryst (BCRX)

Serge Belanger

Needham

$17

Buy

104.82%

Upside

Reiterated

08/04/25

BioCryst's Strong Performance and Growth Potential Justifies Buy Rating

Brian Abrahams

RBC Capital

$13

Buy

56.63%

Upside

Reiterated

08/04/25

BioCryst (BCRX) Gets a Buy from RBC Capital

Tazeen Ahmad

Bank of America Securities

$15

Buy

80.72%

Upside

Reiterated

08/04/25

BioCryst's Strong Q2 Performance and Unique Market Position Justify Buy Rating

Gena Wang

Barclays

$8→$11

Hold

32.53%

Upside

Reiterated

05/07/25

Barclays Sticks to Its Hold Rating for BioCryst (BCRX)

Liisa Bayko

Evercore ISI

$12

Buy

44.58%

Upside

Reiterated

05/06/25

Evercore ISI Keeps Their Buy Rating on BioCryst (BCRX)

Jessica Fye

J.P. Morgan

$10→$13

Buy

56.63%

Upside

Reiterated

05/06/25

J.P. Morgan Remains a Buy on BioCryst (BCRX)

Maury Raycroft

Jefferies

$12→$14

Buy

68.67%

Upside

Reiterated

05/05/25

BioCryst Pharma (BCRX) PT Raised to $14 at JefferiesJefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $14.00 (from $12.00) while maintaining a Buy rating.

Stacy Ku

TD Cowen

$20

Buy

140.96%

Upside

Reiterated

05/05/25

BioCryst's Orladeyo Surpasses Expectations: A Strong Buy Recommendation

Steven Seedhouse

Cantor Fitzgerald

$20

Buy

140.96%

Upside

Initiated

04/28/25

BioCryst initiated with an Overweight at Cantor FitzgeraldBioCryst initiated with an Overweight at Cantor Fitzgerald

Jonathan Wolleben

Citizens JMP

$18

Buy

116.87%

Upside

Reiterated

04/23/25

Citizens JMP reiterates Market Outperform Rating on BioCryst Pharma (BCRX)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on BioCryst Pharma (NASDAQ: BCRX).

Christopher Raymond

Piper Sandler

$20

Buy

140.96%

Upside

Assigned

10/23/24

Piper Sandler Sticks to Its Buy Rating for BioCryst (BCRX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dex Genotek

TR | OpenAI - 4o

$8.5

Hold

2.41%

Upside

Reiterated

08/08/25

Andrew Fein

H.C. Wainwright

$30

Buy

261.45%

Upside

Reiterated

08/05/25

Laura Chico

Wedbush

$18

Buy

116.87%

Upside

Reiterated

08/05/25

Wedbush Sticks to Their Buy Rating for BioCryst (BCRX)

Serge Belanger

Needham

$17

Buy

104.82%

Upside

Reiterated

08/04/25

BioCryst's Strong Performance and Growth Potential Justifies Buy Rating

Brian Abrahams

RBC Capital

$13

Buy

56.63%

Upside

Reiterated

08/04/25

BioCryst (BCRX) Gets a Buy from RBC Capital

Tazeen Ahmad

Bank of America Securities

$15

Buy

80.72%

Upside

Reiterated

08/04/25

BioCryst's Strong Q2 Performance and Unique Market Position Justify Buy Rating

Gena Wang

Barclays

$8→$11

Hold

32.53%

Upside

Reiterated

05/07/25

Barclays Sticks to Its Hold Rating for BioCryst (BCRX)

Liisa Bayko

Evercore ISI

$12

Buy

44.58%

Upside

Reiterated

05/06/25

Evercore ISI Keeps Their Buy Rating on BioCryst (BCRX)

Jessica Fye

J.P. Morgan

$10→$13

Buy

56.63%

Upside

Reiterated

05/06/25

J.P. Morgan Remains a Buy on BioCryst (BCRX)

Maury Raycroft

Jefferies

$12→$14

Buy

68.67%

Upside

Reiterated

05/05/25

BioCryst Pharma (BCRX) PT Raised to $14 at JefferiesJefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $14.00 (from $12.00) while maintaining a Buy rating.

Stacy Ku

TD Cowen

$20

Buy

140.96%

Upside

Reiterated

05/05/25

BioCryst's Orladeyo Surpasses Expectations: A Strong Buy Recommendation

Steven Seedhouse

Cantor Fitzgerald

$20

Buy

140.96%

Upside

Initiated

04/28/25

BioCryst initiated with an Overweight at Cantor FitzgeraldBioCryst initiated with an Overweight at Cantor Fitzgerald

Jonathan Wolleben

Citizens JMP

$18

Buy

116.87%

Upside

Reiterated

04/23/25

Christopher Raymond

Piper Sandler

$20

Buy

140.96%

Upside

Assigned

10/23/24

Piper Sandler Sticks to Its Buy Rating for BioCryst (BCRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioCryst

1 Month

xxx

Success Rate

15/23 ratings generated profit

Average Return

+7.83%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.22% of your transactions generating a profit, with an average return of +7.83% per trade.

3 Months

xxx

Success Rate

12/23 ratings generated profit

Average Return

+10.69%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.17% of your transactions generating a profit, with an average return of +10.69% per trade.

1 Year

Brian AbrahamsRBC Capital

Success Rate

13/17 ratings generated profit

Average Return

+17.93%

reiterated a buy rating 8 days ago

Copying Brian Abrahams's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +17.93% per trade.

2 Years

xxx

Success Rate

13/17 ratings generated profit

Average Return

+18.89%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 76.47% of your transactions generating a profit, with an average return of +18.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BCRX Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BCRX has received 12 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. BCRX average Analyst price target in the past 3 months is 16.92.

Each month's total comprises the sum of three months' worth of ratings.

BCRX Financial Forecast

BCRX Earnings Forecast

Next quarter’s earnings estimate for BCRX is $0.03 with a range of $0.01 to $0.07. The previous quarter’s EPS was $0.02. BCRX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.61% of the time in the same period. In the last calendar year BCRX has Outperformed its overall industry.

BCRX Sales Forecast

Next quarter’s sales forecast for BCRX is $162.24M with a range of $156.00M to $166.22M. The previous quarter’s sales results were $163.35M. BCRX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year BCRX has Outperformed its overall industry.

BCRX Stock Forecast FAQ

What is BCRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Biocryst Pharmaceuticals’s 12-month average price target is 16.92.

What is BCRX’s upside potential, based on the analysts’ average price target?

Biocryst Pharmaceuticals has 103.86% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BCRX a Buy, Sell or Hold?

Biocryst Pharmaceuticals has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Biocryst Pharmaceuticals’s price target?

The average price target for Biocryst Pharmaceuticals is 16.92. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $8.50. The average price target represents 103.86% Increase from the current price of $8.3.

What do analysts say about Biocryst Pharmaceuticals?

Biocryst Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of BCRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BioCryst (BCRX) Stock Forecast & Price Target

BCRX Analyst Ratings

BCRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioCryst

BCRX Analyst Recommendation Trends

BCRX Financial Forecast

BCRX Earnings Forecast

BCRX Sales Forecast

BCRX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts